PNBN News

• 

  FDA’s CAR-T safety probe; AbbVie’s $10B ADC wager; Pfizer’s GLP-1 setback; Acelyrin’s CRO drama; and more

  December 2, 2023 Comments Off on FDA’s CAR-T safety probe; AbbVie’s $10B ADC wager; Pfizer’s GLP-1 setback; Acelyrin’s CRO drama; and more

• 

  Pfizer, Idorsia and AbbVie drug brands lead the way in pharma digital marketing — study

  December 1, 2023 Comments Off on Pfizer, Idorsia and AbbVie drug brands lead the way in pharma digital marketing — study

• 

  After 4 ratings downgrades in 2 years, Catholic Health gets good news

  December 1, 2023 Comments Off on After 4 ratings downgrades in 2 years, Catholic Health gets good news

• 

  Endo debuts unscripted pool hall video series to promote its Peyronie’s disease drug

  December 1, 2023 Comments Off on Endo debuts unscripted pool hall video series to promote its Peyronie’s disease drug

• 

  DUPIXENT Drug Insights and Market Forecasts Report, 2019-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

  December 1, 2023 Comments Off on DUPIXENT Drug Insights and Market Forecasts Report, 2019-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

• 

  Tharimmune’s public offering; Culmination Bio raises $10M; Pepper Bio’s seed round led by NFX

  December 1, 2023 Comments Off on Tharimmune’s public offering; Culmination Bio raises $10M; Pepper Bio’s seed round led by NFX

• 

  STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal

  December 1, 2023 Comments Off on STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal

• 

  Johnson & Johnson bets heavy on AI-driven drug discovery

  December 1, 2023 Comments Off on Johnson & Johnson bets heavy on AI-driven drug discovery

• 

  Pfizer cans twice-daily oral obesity program after half of patients leave trial while once daily continues

  December 1, 2023 Comments Off on Pfizer cans twice-daily oral obesity program after half of patients leave trial while once daily continues

• 

  Amylyx hires new CMO from Ultragenyx; Eliot Forster is back as a CEO after F-star sale

  December 1, 2023 Comments Off on Amylyx hires new CMO from Ultragenyx; Eliot Forster is back as a CEO after F-star sale